I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and now Xconomy.
What a week. The 21st Century Cures Act is now waiting President Obama’s promised signature after easy passage through Congress. President-elect Donald Trump re-stirred the drug-pricing pot with comments in Time... Read more »
Speaking at a conference in San Francisco Wednesday, geneticist Craig Venter revealed that he had just had surgery for prostate cancer three weeks ago. A health workup at his own high-end... Read more »
Juno Therapeutics is still mulling next steps for its lead product, an experimental cancer immunotherapy now stuck in limbo because five of 68 adult leukemia patients in its current study, a... Read more »
The U.S. Senate cleared the way for the 21st Century Cures Act, an omnibus healthcare spending and reform bill, by voting 85-13 to end debate this evening.
It passed the House... Read more »
[Updated, 12/5/16, 4 p.m. See below.] If you’re following cancer immunotherapy, you might feel a bit swamped by this week’s wave of clinical data from experimental programs that turn... Read more »
By a 392 to 26 vote, the U.S. House of Representatives has passed the omnibus healthcare legislation called the 21st Century Cures Act, bringing new funding for top Obama administration health... Read more »
Two big pieces of the Trump healthcare puzzle have fallen into place. The President-elect’s transition team has nominated Georgia Republican congressman Tom Price to be Health and Human Services secretary. It... Read more »
Juno Therapeutics (NASDAQ: JUNO), a developer of experimental “CAR-T” cancer therapies derived from a patient’s own immune cells, reported this morning that two more patients have died during a trial... Read more »
[Updated, 11/22/16, 5:42 p.m. See below.] Among the many questions swirling around the incoming Trump administration is the fate of ambitious biomedical science projects that require federal funding. What... Read more »
Speculation swirled this week around the incoming U.S. president’s intent to make good on his angry campaign rhetoric on drug prices, while the Associated Press reported that naming-and-shaming—that is, Congress hauling... Read more »
Stem cell transplants are risky business, and although their use to treat cancer and other blood-borne diseases has increased in recent years, they remain dangerous and in many cases a last... Read more »
The incoming Trump administration has posted an outline of its healthcare agenda on its transition website. There is no mention of drug pricing or what the administration might do about frequent... Read more »
[Updated, 11/9/16, 1:20 p.m. See below.] The 2016 U.S. election is over. The country has been rocked by the presidential race, with Donald Trump taking the White House.
Every... Read more »
Our previous roundup came out last week before news broke that Susan Lindquist, a highly decorated and thoughtful researcher into the inner workings of proteins, passed away. She was 67.... Read more »
The polls are tightening. Millions of people are still making up their minds. National figures are making last-minute pitches. The decision could have huge implications for people across the U.S.
We’re... Read more »
[Updated, 11/3/16, 11:43 a.m. See below.] Some of the world’s largest non-profit cancer treatment centers are pooling patient information to gain new insights into the disease and potentially find... Read more »
Unity Biotechnology launched earlier this year to tackle common diseases such as knee arthritis, glaucoma, and clogged arteries in a new way. The company said Thursday it has raised $116 million... Read more »
The FDA has approved the use of pembrolizumab (Keytruda) for some previously untreated patients with a certain type of lung cancer, the drug’s owner Merck (NYSE: MRK) announced late Monday... Read more »
If you’re among those frustrated by the lack of talk about health and science in the three presidential debates, this week perhaps brought you a wee consolation prize. The steady drip... Read more »
December 15, 2016
© 2007-2016, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.